ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly

• Published in: Endocrinología, diabetes y nutrición. Vol. 66; no. 5; pp. 320 - 329
• Main Authors: Álvarez-Escolá, Cristina, Venegas-Moreno, Eva María, García-Arnés, Juan Antonio, Blanco-Carrera, Concepción, Marazuela-Azpiroz, Mónica, Gálvez-Moreno, María Ángeles, Menéndez-Torre, Edelmiro, Aller-Pardo, Javier, Salinas-Vert, Isabel, Resmini, Eugenia, Torres-Vela, Elena María, Gonzalo-Redondo, María Ángeles, Vílchez-Joya, Ricardo, de Miguel-Novoa, María Paz, Halperín-Rabinovich, Irene, Páramo-Fernández, Concepción, de la Cruz-Sugranyes, Guillermo, Houchard, Aude, Picó-Alfonso, Antonio Miguel
• Format: Journal Article
• Language: English
• Published: Elsevier España, S.L.U 01-05-2019
• Subjects: Acromegalia; Acromegaly; Dosage regimens; Endocrinology and Metabolism; Factor de crecimiento de la insulina (IGF-I); Growth hormone (GH); Hormona del crecimiento (GH); Insulin-like growth factor (IGF-I); Lanreotide; Lanreótida; Patrones de dosificación; Somatulina Autogel; Somatuline Autogel; Factor de crecimiento de la insulina (IGF-I); Lanreotide; Patrones de dosificación; Somatulina Autogel; Acromegaly; Hormona del crecimiento (GH); Dosage regimens; Growth hormone (GH); Insulin-like growth factor (IGF-I); Lanreótida; Somatuline Autogel; Acromegalia
• DOI: 10.1016/j.endien.2019.05.002
• EISSN: 2530-0180

AbstractObjectivesThe ACROSTART study was intended to determine the time to achieve normalization of GH and IGF-I levels in responding patients with acromegaly administered different dosage regimens of lanreotide Autogel (Somatuline ® Autogel ®). MethodsFrom March 2013 to October 2013, clinical data from 57 patients from 17 Spanish hospitals with active acromegaly treated with lanreotide for ≥4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalized IGF-I levels in ≥2 measurements) were analyzed. The primary objective was to determine the time from start of lanreotide treatment to hormonal normalization. ResultsMedian patient age was 64 years, 21 patients were male, 39 patients had undergone surgery, and 14 patients had received radiotherapy. Median hormonal values at start of lanreotide treatment were: GH, 2.6 ng/ml; IGF-I, 1.6 × ULN. The most common starting dose of lanreotide was 120 mg (29 patients). The main initial regimens were 60 mg/4 weeks ( n= 13), 90 mg/4 weeks ( n= 6), 120 mg/4 weeks ( n= 13), 120 mg/6 weeks ( n= 6), and 120 mg/8 weeks ( n= 9). An initial treatment regimen with a long interval (≥6 weeks) was administered in 25 patients. Mean duration of lanreotide treatment was 68 months (7–205). Median time to achieve hormonal control was 4.9 months. Injections were managed without healthcare assistance in 13 patients. Median number of visits to endocrinologists until hormonal control was achieved was 3. Fifty-one patients were “satisfied”/“very satisfied” with treatment and 49 patients did not miss any dose. ConclusionsReal-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals.